文献速递间质性肺疾病

泼尼松龙联合他克莫司与联合环孢素A治疗多发性肌炎/皮肌炎相关间质性肺病的随机开放标签试验

Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial.
PubMed 文献 · Respirology · 2020-11-11

52周无进展生存率TAC组87% vs CsA组71%(P=0.16),总生存率97% vs 93%(P=0.50)。结论提示PSL+TAC可能获得更好的短期PFS率,但需进一步研究长期疗效与安全性。

要点

  • PSL+TAC组52周PFS率87%,PSL+CsA组71%,差异无统计学意义(P=0.16)。
  • 两组52周OS率分别为97%和93%(P=0.50),均无因不良事件停药。
  • 意向性治疗人群未显示显著差异,需进一步研究长期疗效与安全性。

核心结论

  • 泼尼松龙联合他克莫司治疗可能较联合环孢素A获得更好的短期无进展生存率。
  • 需进一步研究评估该方案的长期疗效和安全性。

研究设计与样本

  • 前瞻性多中心、开放标签、随机、52周2期试验。
  • 主要终点为意向性治疗人群52周无进展生存率。

主要发现

  • 52周PFS率:TAC组87%,CsA组71%(P=0.16)。
  • 52周OS率:TAC组97%,CsA组93%(P=0.50)。
  • 符合方案人群中,两组52周%FVC均较基线显著增加。
  • 无患者因不良事件中断治疗。

关键数值与推荐

  • 主要终点:52周PFS率,TAC组87% vs CsA组71%(P=0.16)。
  • 次要终点:52周OS率,TAC组97% vs CsA组93%(P=0.50)。

临床怎么用

  • 对于PM/DM-ILD初始治疗,PSL联合TAC可能作为优于联合CsA的短期选择。
  • 治疗期间需关注长期疗效与安全性,目前证据限于52周。

局限性

  • 开放标签设计可能引入偏倚。
  • 随访时间仅52周,缺乏长期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The efficacy of combination therapy with corticosteroids and CNI, TAC and CsA, for PM/DM-ILD has been described retrospectively. However, it remains unknown which CNI treatment regimens, TAC or CsA regimens, are more effective as initial treatments for patients with PM/DM-ILD. METHODS: We conducted a prospective multicentre, open-label, randomized, 52-week phase 2 trial. Patients with PM/DM-ILD were randomly allocated to receive PSL plus TAC (TAC group) or PSL plus CsA (CsA group). The primary endpoint was PFS rate in the intention-to-treat population at 52 weeks. The secondary endpoints were OS rate at 52 weeks, changes in pulmonary function tests from baseline to 52 weeks and AE. RESULTS: Fifty-eight patients were randomly assigned to the TAC group (n = 30) and the CsA group (n = 28). The PFS rates at 52 weeks were 87% in the TAC group and 71% in the CsA group (P = 0.16). The OS rates at 52 weeks were 97% in the TAC group and 93% in the CsA group (P = 0.50). The %FVC at 52 weeks in the per-protocol populations significantly increased in both groups. None of the patients discontinued the treatment due to AE. CONCLUSION: PSL plus TAC treatment may achieve a better short-term PFS rate compared with PSL plus CsA treatment. Further studies must be conducted to evaluate the long-term efficacy and safety of such treatment.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Fujisawa T, Hozumi H, Kamiya Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial. Respirology. 2020. PMID: 33179395. doi:10.1111/resp.13978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。